Golimumab, a fully human monoclonal antibody targeting TNF-α, is an established treatment option for patients with moderately to severely active ulcerative colitis (UC) who respond inadequately to, or are intolerant of, conventional therapies. This evidence concerns the gene TNF and ulcerative colitis.